

## Anti-Zika virus(ZIKV)(strain Zika SPH2015) ZIKV-E/Envelope protein(Domain III) Monoclonal Antibody

catalog number: **E-AB-V1335**

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.

### Description


<b>Reactivity</b>	Zika Virus
<b>Immunogen</b>	Recombinant ZIKV E / Envelope protein (Domain III, His Tag)
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Clone</b>	101
<b>Purification</b>	Protein A Affinity
<b>Buffer</b>	0.2 µm filtered solution in PBS.

### Applications

### Recommended Dilution

<b>WB</b>	1:2000-1:10000
-----------	----------------

### Data



Western Blot analysis of Recombinant ZIKV E / Envelope protein (Domain III, His Tag)(PKSV030265 with 5ng) using Anti-Zika virus(ZIKV)(strain Zika SPH2015) ZIKV-E/Envelope protein(Domain III) Monoclonal Antibody at dilution of 1:2000.

### Preparation & Storage

<b>Storage</b>	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
<b>Shipping</b>	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

### Background

Envelope of Zika virus is responsible for receptor binding and membrane. Analysis of the envelope protein of Zika, from Brazilian Zika SPH215 (KU321639), indicates predicted B and T cell epitopes in peptides that are consistent to those reported for dengue, YFV and Japanese encephalitis. The envelope Domain II B cell epitope, to which much dengue non-neutralizing cross reaction is attributed, is also conserved also in Zika virus, consistent with prior field observations of cross reactivity with dengue and YF. Domain III of the Zika envelope protein, likely the main specific neutralizing domain, is distinct from recent Brazilian dengue isolates and a recent Peruvian YF isolate (GQ379163), 76% of possible major histocompatibility complex class (MHC) I and MHC II binding peptides and potential B cell linear epitopes are unique to Zika virus.

### For Research Use Only